<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555111</url>
  </required_header>
  <id_info>
    <org_study_id>AOM 11077 - P 110150</org_study_id>
    <secondary_id>2015-001190-40</secondary_id>
    <nct_id>NCT02555111</nct_id>
  </id_info>
  <brief_title>Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.</brief_title>
  <acronym>RIPORT</acronym>
  <official_title>Multicentric Randomized Study of Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open randomized therapeutic study to assess the efficacy of Xarelto 15mg/day in the&#xD;
      recurrence of thromboembolic event compared to an untreated group in patients with chronic&#xD;
      portal vein thrombosis without high risk thrombophilia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic portal vein thrombosis (PVT) is a rare disease, affecting young patients,&#xD;
      characterized by permanent obstruction of the portal vein trunk causing portal hypertension.&#xD;
      In 60-70% of cases it is related to high risk, moderate or mild prothrombotic risk factors.&#xD;
&#xD;
      Accordingly, there are 2 types of complications from PVT :(i) gastrointestinal haemorrhage&#xD;
      related to portal hypertension; and (ii) recurrent thrombosis.&#xD;
&#xD;
      Recurrent thrombosis its most dreaded complication as it may lead to intestinal infarction&#xD;
      with a related mortality of 20-60% and a high risk of intestinal insufficiency.&#xD;
&#xD;
      Gastrointestinal haemorrhage related to portal hypertension occurs in 20% patients/year. It&#xD;
      is less frequent in patients treated with medical or endoscopic prophylaxis for variceal&#xD;
      bleeding.&#xD;
&#xD;
      Retrospective data shows that anticoagulation does not worsen the prognosis, and may&#xD;
      conversely improve it. Thus, in patients at risk for gastrointestinal bleeding due to portal&#xD;
      hypertension and a mild or moderate risk of recurrent thrombosis, the benefit-risk ratio of&#xD;
      anticoagulation therapy is unclear.&#xD;
&#xD;
      The aim of this open randomised trial is to assess the efficacy of Xarelto 15mg/day, a new&#xD;
      oral factor Xa inhibitor, in the recurrence of thromboembolic event and the risk of major&#xD;
      bleeding compared to an untreated group in patients with chronic portal vein thrombosis&#xD;
      without high risk thrombophilia.&#xD;
&#xD;
      This is a national, multicentric, interventional study. 17 french centers already agreed to&#xD;
      participate.&#xD;
&#xD;
      296 patients will be included on a 3 years period with 2 to 4 years treatment period. All&#xD;
      data will be collected after informed consent will be obtained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of thromboembolic event in any territory (arterial or venous, splanchnic or extra splanchnic) or death</measure>
    <time_frame>2 years</time_frame>
    <description>In patients with chronic portal vein thrombosis without high risk thrombophilia, to assess the efficacy of Xarelto in the recurrence of thromboembolic event compared to absence of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of xarelto</measure>
    <time_frame>2 years</time_frame>
    <description>Assess the efficacy regarding:&#xD;
- Incidence of Pulmonary embolism, Deep vein thrombosis, Major bleedings and Portal hypertension bleeding, new non bleeding complication of portal hypertension, minor bleeding,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of xarelto</measure>
    <time_frame>2 years</time_frame>
    <description>Assess the safety regarding:&#xD;
Toxicity of Xarelto, especially hepatic.&#xD;
Gastrointestinal clinically relevant non major bleedings related to portal hypertension&#xD;
Other gastrointestinal clinically relevant non major bleedings&#xD;
Other adverse events&#xD;
Survival (12months, 24 months and at the end of the follow up).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalization during follow up.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clotting activator marker with and without Xarelto.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization during follow up.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Chronic Portal Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Xarelto</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg/day oral administration during 2 to 4 years (based on the recruitment date).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>untreated</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>the patient won't receive any treatment during his study participation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xarelto</intervention_name>
    <description>15mg/day oral administration during 2 to 4 years (based on the recruitment date).</description>
    <arm_group_label>Xarelto</arm_group_label>
    <other_name>Rivaroxaban</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  90 years old &gt;Adults &gt; 18 years old&#xD;
&#xD;
          -  Patients Either affected by cavernous portal, with a constituted diagnostic on&#xD;
             radiological criteria, treated or not with anticoagulant Or acute portal thrombosis&#xD;
             history dating back more than 6 months, documented by angiography or angio-MRI ;&#xD;
             followed or not by a repermeabilize.&#xD;
&#xD;
          -  Patient who was used prophylaxis for gastrointestinal bleeding in portal hypertension,&#xD;
             according to current consensus recommendations for patients with cirrhosis&#xD;
&#xD;
          -  Barrier contraception or intrauterine device (with or without progestin), for women of&#xD;
             childbearing age, or progestin alone. Do not use combined hormonal contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a high risk factor of recurrence of thrombosis veinous after review of the&#xD;
             medical file by a validation committee composed of an hepatologist and a hematologist&#xD;
             physician hemostasis specialist.&#xD;
&#xD;
          -  Disease with relevant coagulopathy and bleeding risk clinically relevant (platelet &lt;&#xD;
             50 000, or TP &lt;30 % without AVK or Factor V &lt; 30% ou fibrinogen &lt; 0.8)&#xD;
&#xD;
          -  Cirrhosis clinically relevant or with histological test or Budd Chiari syndrome.&#xD;
&#xD;
          -  Personnel or first degree familial past history of spontaneous (unprovoked) deep vein&#xD;
             thrombosis require an anticoagulant treatment&#xD;
&#xD;
          -  Pregnancy and breast feeding women&#xD;
&#xD;
          -  Past history of mesenteric infarction&#xD;
&#xD;
          -  Absolute necessity of anticoagulation whatever the cause&#xD;
&#xD;
          -  Galactose intolerance, Lapp lactase deficiency, malabsorption of glucose and galactose&#xD;
&#xD;
          -  HIV positive and treated by antiprotease&#xD;
&#xD;
          -  Patient with impossible follow up&#xD;
&#xD;
          -  Severe renal failure (creatinin clearance &lt; 30 ml/min)&#xD;
&#xD;
          -  Concomitant treatment with ketoconazole, l'itraconazole, le voriconazole or&#xD;
             posaconazole, or HIV protease inhibitor, potent CYP3A4 and P-gp inhibitors&#xD;
&#xD;
          -  Simultaneous treatment with rifampicin or other CYP3A4 inductor&#xD;
&#xD;
          -  Hypersensitivity to Xarelto or one of the excipients&#xD;
&#xD;
          -  Progressive bleeding, clinically relevant including lesion or disease with significant&#xD;
             risk of major bleeding.&#xD;
&#xD;
          -  Concomitant treatment with other anticoagulant (unfractionated heparin (UFH), low&#xD;
             molecular weight heparin (enoxaparin, dalteparin, etc.), heparin derivatives&#xD;
             (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban,&#xD;
             etc.), unless relay with Xarelto® or &quot;vice-versa&quot;, or when administered at doses f UFH&#xD;
             necessary to maintain the permeability of a central venous or arterial catheter.&#xD;
&#xD;
          -  Concomitant treatment of acute coronary syndrome clopidogrel / Plavix®&#xD;
&#xD;
          -  Liver transplantation&#xD;
&#xD;
          -  Transjugular intrahepatic portosystemic shunt&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurélie Dr Plessier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Beaujon - APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2015</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

